Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy
Summary
Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY
Application US20260097021A1 Kind: A1 Apr 09, 2026
Inventors
Fady MALIK, Stuart KUPFER, Stephen B. HEITNER, Laura Ann ROBERTSON, Lixin MENG, Anna OSMUKHINA, Qi WOHLTMAN
Abstract
Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.
CPC Classifications
A61K 31/4245 A61P 9/00 A61P 9/06
Filing Date
2025-07-01
Application No.
19257352
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.